On October 9, 2015 the Board of Directors of Regen Biopharma Inc. appointed Harry M. Lander, Ph.D., M.B.A., age 50, to the position of President. Prior to accepting the office of President at Regen, Dr. Lander served as Research Chief-Administration at Sidra Medical and Research Center. The President, reporting directly to the CEO, will develop a robust strategic plan and vision for the advancement of Regen's research into commercial products.

The President leads the growth of Regen's technology, whether from in-house research or through corporate or academic partnerships, business development, and commercialization initiatives to support Regen's vision. He/she leads the development of the commercial innovation capability at Regen to execute a quantifiable business development strategy to catalyze the development of new products and services.